AAA
TRAX

Affinity Asset Advisors’s First Tracks Biotherapeutics TRAX Stock Holding History

Affinity Asset Advisors’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.9M Buy
+2,032,012
New +$38M 1.85% 15

Other funds holding TRAX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Affinity Asset Advisors's TRAX Position: Q2 2026 in Review

Affinity Asset Advisors opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 2,032,012 shares worth $40.9M. The stake represents 1.85% of the portfolio and ranks #15 among its holdings.

89 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

  • Affinity Asset Advisors held 2,032,012 shares of First Tracks Biotherapeutics worth $40.9M as of Q2 2026.
  • First Tracks Biotherapeutics was a new Affinity Asset Advisors position in Q2 2026.
  • First Tracks Biotherapeutics made up 1.85% of Affinity Asset Advisors's portfolio in Q2 2026, its #15 holding.
  • 89 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.